
BioStack raises $9.5 million to build longitudinal datasets for medical AI
The AMW Read
The seed round adds a healthcare data supplier to the player map, but reported record access lacks model-performance evidence and supports sub-segment significance.
BioStack raises $9.5 million to build longitudinal datasets for medical AI
San Francisco-based BioStack raised $9.5 million in seed funding led by Peak XV, DCVC and Afore Capital. Its valuation was not disclosed. Founded in 2025, the healthcare data startup joined Y Combinator's Spring 2026 batch and has 11 employees. The funding will support US and international expansion, platform development, and engineering and research hiring.
BioStack targets a bottleneck in healthcare AI: linking scattered clinical information into records that follow patients over time. It combines clinical notes, laboratory results, imaging, medications, treatment histories and outcomes into datasets for research, drug development, and model training and evaluation. The company says its hospital network spans the US, India, Brazil and Argentina, with access to more than 100 million de-identified patient records. This places BioStack in healthcare AI's data supply layer, where linked treatment and outcome histories are the proposed value. The reported access figure does not establish how many records are prepared for model development.
For builders and investors, the concrete diligence question is how much of that claimed access becomes usable, linked data for a specific task. BioStack reports combining hundreds of thousands of scans and millions of telehealth audio transcripts with other clinical records. These are company claims; the report provides no model-performance results. Buyers should therefore assess dataset completeness and suitability for their intended use before treating record volume as evidence of training value.